The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
A Decade of Direct-to-Consumer Advertising of Prescription Drugs
Open accessAbstract
BACKGROUND: Evidence suggests that direct-to-consumer advertising of prescription drugs increases pharmaceutical sales and both helps to avert underuse of medicines and leads to potential overuse. Concern about such advertising has increased recently owing to the withdrawal from the market of heavily advertised drugs found to carry serious risks. Moreover, the Food and Drug Administration (FDA) has been criticized for its weak enforcement of laws regulating such advertising. METHODS: We examined industry-wide trends in spending by pharmaceutical companies on direct-to-consumer advertising and promotion to physicians during the past decade. We characterized the drugs for which such advertising is used and assessed the timing of advertising after a drug is introduced. Finally, we examined trends in the FDA's regulation of drug advertising. RESULTS: Total spending on pharmaceutical promotion grew from $11.4 billion in 1996 to $29.9 billion in 2005. Although during that time spending on direct-to-consumer advertising increased by 330%, it made up only 14% of total promotional expenditures in 2005. Direct-to-consumer campaigns generally begin within a year after the approval of a product by the FDA. In the context of regulatory changes requiring legal review before issuing letters, the number of letters sent by the FDA to pharmaceutical manufacturers regarding violations of drug-advertising regulations fell from 142 in 1997 to only 21 in 2006. CONCLUSIONS: Spending on direct-to-consumer advertising has continued to increase in recent years in spite of the criticisms leveled against it. Our findings suggest that calls for a moratorium on such advertising for new drugs would represent a dramatic departure from current practices.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kravitz, R. L., Epstein, R. M., Feldman, M. D., Franz, C. E., Azari, R., Wilkes, M. S., Hinton, L., & Franks, P. (2005) · JAMA · doi:10.1001/jama.293.16.1995 · Cited by 586
Promotion of Prescription Drugs to Consumers
Rosenthal, M. B., Berndt, E. R., Donohue, J. M., Frank, R. G., & Epstein, A. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmsa012075 · Cited by 420
Self-citationPharmaceuticals in U.S. Health Care: Determinants of Quantity and Price
Berndt, E. R. (2002) · Journal of Economic Perspectives · doi:10.1257/089533002320950975 · Cited by 171
Direct-to-Consumer Advertising — Education or Emotion Promotion?
Wolfe, S. M. (2002) · New England Journal of Medicine · doi:10.1056/nejm200202143460713 · Cited by 152
Effects of Pharmaceutical Promotion on Adherence to the Treatment Guidelines for Depression
Donohue, J. M., Berndt, E. R., Rosenthal, M. B., Epstein, A. M., & Frank, R. G. (2004) · Medical Care · doi:10.1097/00005650-200412000-00004 · Cited by 149
Self-citationThe Effect of Prescription Drug Advertising on Doctor Visits
Iizuka, T., & Jin, G. Z. (2005) · Journal of Economics & Management Strategy · doi:10.1111/j.1530-9134.2005.00079.x · Cited by 146
Demand Effects of Recent Changes in Prescription Drug Promotion
Rosenthal, M. B., Berndt, E. R., Donohue, J. M., Epstein, A. M., & Frank, R. G. (2003) · Forum for Health Economics & Policy · doi:10.2202/1558-9544.1044 · Cited by 131
Self-citationEffects of Direct-to-Consumer Advertising on Medication Choice: The Case of Antidepressants
Donohue, J. M., & Berndt, E. R. (2004) · Journal of Public Policy & Marketing · doi:10.1509/jppm.23.2.115.51395 · Cited by 122
Self-citationDirect-to-Consumer Advertising
Hollon, M. F. (2005) · JAMA · doi:10.1001/jama.293.16.2030 · Cited by 105
What Explains the Use of Direct‐to‐Consumer Advertising of Prescription Drugs?
Iizuka, T. (2004) · Journal of Industrial Economics · doi:10.1111/j.0022-1821.2004.00230.x · Cited by 85
Bradford, W. D., Kleit, A. N., Nietert, P. J., Steyer, T. E., McIlwain, T. F., & Ornstein, S. M. (2006) · Health Affairs · doi:10.1377/hlthaff.25.5.1371 · Cited by 70
Cited by
Trends in Prescription Drug Use Among Adults in the United States From 1999-2012
Kantor, E. D., Rehm, C. D., Haas, J. S., Chan, A. T., & Giovannucci, E. L. (2015) · JAMA · doi:10.1001/jama.2015.13766 · Cited by 1,219
National Patterns in Antidepressant Medication Treatment
Olfson, M., & Marcus, S. C. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.81 · Cited by 730
Tannenbaum, C., Martin, P., Tamblyn, R., Benedetti, A., & Ahmed, S. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.949 · Cited by 665
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform
Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016) · JAMA · doi:10.1001/jama.2016.11237 · Cited by 592
Polypharmacy Among Adults Aged 65 Years and Older in the United States: 1988–2010
Charlesworth, C. J., Smit, E., Lee, D. S. H., Alramadhan, F., & Odden, M. C. (2015) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glv013 · Cited by 570
Metadata
- Authors
- Donohue, J. M., Cevasco, M., & Rosenthal, M. B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-08-16
- Volume
- 357
- Issue
- 7
- Pages
- 673-681
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2170551470
- Cited by
- 512
- References
- 11
- FWCI
- 41.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.